Europe Shingles Vaccine Market Size & Outlook, 2025-2030
Europe shingles vaccine market highlights
- The Europe shingles vaccine market generated a revenue of USD 1,175.8 million in 2024.
- The market is expected to grow at a CAGR of 16% from 2025 to 2030.
- In terms of segment, shingrix was the largest revenue generating product in 2024.
- Shingrix is the most lucrative product segment registering the fastest growth during the forecast period.
Europe data book summary
| Market revenue in 2024 | USD 1,175.8 million |
| Market revenue in 2030 | USD 2,812.4 million |
| Growth rate | 16% (CAGR from 2025 to 2030) |
| Largest segment | Shingrix |
| Fastest growing segment | Shingrix |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Shingrix |
| Key market players worldwide | Merck & Co Inc, Skye Bioscience Inc Ordinary Shares, Green Cross Health Ltd, Barinthus Biotherapeutics PLC ADR, CanSino Biologics Inc Class H, GSK PLC, GeneOne Life Science |
Other key industry trends
- In terms of revenue, Europe region accounted for 24.6% of the global shingles vaccine market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,404.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Shingles Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GeneOne Life Science | View profile | - | Soeul, Ch'ungch'ong-namdo, South Korea, Asia | https://www.genels.com/index.asp |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
| Barinthus Biotherapeutics PLC ADR | View profile | 130 | Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, United Kingdom, OX11 0DF | https://www.barinthusbio.com |
| Green Cross Health Ltd | View profile | - | 602 Great South Road, Ellerslie, Ground Floor, Building B, Millennium Centre, Auckland, NTL, New Zealand, 1051 | https://www.greencrosshealth.co.nz |
| Skye Bioscience Inc Ordinary Shares | View profile | 11 | 11250 El Camino Real, Suite 100, San Diego, CA, United States, 92130 | https://www.skyebioscience.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
Europe shingles vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to shingles vaccine market will help companies and investors design strategic landscapes.
Shingrix was the largest segment with a revenue share of 113.65% in 2024. Horizon Databook has segmented the Europe shingles vaccine market based on shingrix covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe shingles vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe shingles vaccine market databook
-
Our clientele includes a mix of shingles vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe shingles vaccine market , including forecasts for subscribers. This continent databook contains high-level insights into Europe shingles vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
